Currently, there are 333.93M common shares owned by the public and among those 271.58M shares have been available to trade.
The company’s stock has a 5-day price change of 17.14% and -45.33% over the past three months. IOVA shares are trading -72.30% year to date (YTD), with the 12-month market performance down to -74.69% lower. It has a 12-month low price of $1.64 and touched a high of $12.51 over the same period. IOVA has an average intraday trading volume of 12.38 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.08%, -23.86%, and -69.14% respectively.
Institutional ownership of Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares accounts for 64.00% of the company’s 333.93M shares outstanding.
It has a market capitalization of $684.57M and a beta (3y monthly) value of 0.86. The earnings-per-share (ttm) stands at -$1.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.46% over the week and 14.65% over the month.
Analysts forecast that Iovance Biotherapeutics Inc (IOVA) will achieve an EPS of -0.27 for the current quarter, -0.25 for the next quarter and -0.71 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.34 while analysts give the company a high EPS estimate of -0.34. Comparatively, EPS for the current quarter was -0.34 a year ago. Earnings per share for the fiscal year are expected to increase by 12.10%, and 31.29% over the next financial year. EPS should grow at an annualized rate of 47.62% over the next five years, compared to 4.17% over the past 5-year period.
Looking at the support for the IOVA, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on May 16, 2025, with the firm’s price target at $2. Citizens JMP was of a view on May 09, 2025 that the stock is Mkt Perform, while UBS gave the stock Buy rating on October 24, 2024, issuing a price target of $17. Piper Sandler on their part issued Neutral rating on July 29, 2024.
